BTCC / BTCC Square / Global Cryptocurrency /
CSL Shares Gain on Lilly Partnership and Buyback Momentum

CSL Shares Gain on Lilly Partnership and Buyback Momentum

Published:
2026-02-19 09:02:02
6
2
BTCCSquare news:

CSL Limited (CSL.AX) ROSE 0.95% to A$154.19, extending gains for a second session as investors responded to strategic moves. The biopharma firm secured a US$100 million upfront payment from Eli Lilly for clazakizumab rights, retaining cardiovascular application exclusivity. Its ongoing share repurchase program further buoyed sentiment.

Market-wide risk appetite lifted the S&P/ASX 200 by 0.9%, though CSL remains 15% below February peaks. The deal structure—milestone payments plus royalties—offers long-term revenue optionality while buybacks provide technical support. An April interim dividend maintains capital return focus amid earnings season volatility.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.